Inventiva (NASDAQ:IVA) Sees Unusually-High Trading Volume - Here's What Happened

Key Points

• Inventiva S.A. experienced a 12% increase in trading volume, with 28,678 shares traded on Monday compared to 25,561 shares in the previous session.
• Guggenheim raised their target price for Inventiva from $9.00 to $13.00 and assigned a "buy" rating, while Piper Sandler set an "overweight" rating with a $26.00 target.
• The company, currently in Phase III trials for its lead product candidate, Lanifibranor, focuses on therapies for non-alcoholic steatohepatitis (NASH) and related conditions.

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) saw strong trading volume on Monday . 28,678 shares changed hands during mid-day trading, an increase of 12% from the previous session's volume of 25,561 shares.The stock last traded at $6.02 and had previously closed at $6.05.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Guggenheim boosted their target price on Inventiva from $9.00 to $13.00 and gave the company a "buy" rating in a research note on Tuesday, September 2nd. Piper Sandler initiated coverage on Inventiva in a report on Wednesday, August 27th. They set an "overweight" rating and a $26.00 price target on the stock. Finally, HC Wainwright initiated coverage on Inventiva in a report on Wednesday, September 3rd. They set a "buy" rating and a $20.00 price target on the stock. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, Inventiva presently has an average rating of "Moderate Buy" and an average price target of $14.83.

Inventiva Price Performance

The firm has a 50 day moving average of $4.61 and a two-hundred day moving average of $3.75.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Inventiva stock. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 10,715 shares of the company's stock, valued at approximately $32,000. 19.06% of the stock is currently owned by institutional investors and hedge funds.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.